Pharmaceutical compositions comprising synthetic peptide...

Details Pharmaceutical compositions comprising synthetic peptide... Pharmaceutical compositions comprising synthetic peptide...

2006-05-30

2006-05-30

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S013800, C514S014800, C530S324000, C530S325000, C530S326000

Reexamination Certificate

active

07053043

ABSTRACT:
Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.

REFERENCES:
patent: 4339431 (1982-07-01), Gaffar
patent: 5182262 (1993-01-01), Leto
patent: 5204099 (1993-04-01), Barbier et al.
patent: 5500412 (1996-03-01), Carney et al.
patent: 5858964 (1999-01-01), Aharoni et al.
patent: 5958882 (1999-09-01), Jameson et al.
patent: 5962634 (1999-10-01), Jameson et al.
patent: 6046289 (2000-04-01), Komazawa et al.
patent: 6075004 (2000-06-01), Benedict et al.
patent: 6180600 (2001-01-01), Jameson et al.
patent: 6436903 (2002-08-01), Clayberger et al.
patent: 6844421 (2005-01-01), Korngold et al.
patent: WO 92/02543 (1992-02-01), None
patent: WO 94/26774 (1994-11-01), None
patent: WO 95/26980 (1995-10-01), None
patent: WO 95/31997 (1995-11-01), None
patent: WO 96/32119 (1996-10-01), None
Sigma Catalog, 1991 Edition, pp. 1045-1050.
Wagner (Introduction to Statistics, pp. 82-140, Harper Collins Publishers, 1992).
Aharoni, Transplantation 72, 598-605, 2001.
Aharoni et al, “Studies on the mechanism and specificity of the effect of the synthetic random coploymer GLAT on graft-versus-host disease”,Immunol Lett58(2):79-87 (1997).
Fridkis-Hareli et al, “Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells—specificity and promiscuity”,Proc Natl Acad Sci USA91(11):4872-4876 (1994).
Fridkis-Hareli et al, “Binding of random copolymers of three amino acids to class II MHC molecules”,Int. Immunol11(5):635-641 (1999).
Li et al, “Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma”,Eur J Pharmacol342(2-3):303-310 (1998).
Schlegel et al, “A synthetic random basic copolymer with promicuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative response to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo”,Proc Natl Acad Sci USA93(10):5061-5066 (1996).
Sela et al, “Suppressive activity of COP-1 in EAE and its relevance to multiple sclerosis”,Bull Inst Pasteur88:303-314 (1990).
Teitelbaum et al, “Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide”,Eur J Immunol1(4):242-248 (1971).
Teitelbaum et al, “Cross-reaction and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1”,Proc Natl Acad Sci USA88(21):9528-19532 (1991).
Teitelbaum et al, “Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein”,Proc Natl Acad Sci USA89(1):137-141 (1992).
Teitelbaum et al, “Copolymer 1 from the laboratory to FDA”,Isr J Med Sci33(4):280-284 (1997).
Aharoni et al, “Copolymer 1 induces T cells of the T helper type 2 the crossreact with myelin basic protein and supperss experimental autoimmune encephalomyelitis”,Proc Natl Acad Sci USA94(20):10821-10826 (1997).
Arnon et al, “New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis”,J Neurol243(4 Suppl 1):S8-13 (1996).
Johnson et al, “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial”,Neurology45:1268-1276 (1995).
Schlegel et al, “Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules”,Blood84(8):2802-2810 (1994).
Teitelbaum et al, “Development of Copolymer 1 (Copaxone®) as a Specific Drug Against Multiple Sclerosis”, inThe Decade of Autoimmunity, Y. Shoenfeld, ed., Elsevier Science B.V., pp 191-196 (1999).

Affiliated with

Also associated with

Rating

Pharmaceutical compositions comprising synthetic peptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions comprising synthetic peptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising synthetic peptide... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3602877